Cephalon completes Mepha aquisition

Cephalon, a US biopharmaceutical company, has completed its acquisition of Mepha, a Swiss pharmaceutical company, at a purchase price of CHF662.4m (£407.4m).

As a result of the acquisition, Mepha is now a wholly owned subsidiary of Cephalon.

The purchase price is subject to further post-closing working capital and net debt adjustments.